C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation

Research output: Contribution to journalReview article

Authors

External organisations

  • University of Toronto

Abstract

The C-type lectin domain (CTLD) group 14 family of transmembrane glycoproteins consist of thrombomodulin, CD93, CLEC14A and CD248 (endosialin or tumour endothelial marker-1). These cell surface proteins exhibit similar ectodomain architecture and yet mediate a diverse range of cellular functions, including but not restricted to angiogenesis, inflammation and cell adhesion. Thrombomodulin, CD93 and CLEC14A can be expressed by endothelial cells, whereas CD248 is expressed by vasculature associated pericytes, activated fibroblasts and tumour cells among other cell types. In this article, we review the current literature of these family members including their expression profiles, interacting partners, as well as established and speculated functions. We focus primarily on their roles in the vasculature and inflammation as well as their contributions to tumour immunology. The CTLD group 14 family shares several characteristic features including their ability to be proteolytically cleaved and engagement of some shared extracellular matrix ligands. Each family member has strong links to tumour development and in particular CD93, CLEC14A and CD248 have been proposed as attractive candidate targets for cancer therapy.

Bibliographic note

© 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Details

Original languageEnglish
Pages (from-to)3299-3332
Number of pages34
JournalThe FEBS journal
Volume286
Issue number17
Early online date9 Jul 2019
Publication statusPublished - 2 Sep 2019

Keywords

  • C-type lectin, CD248, CD93, CLEC14A, cancer, extracellular matrix, group XIV, immuno-oncology, thrombomodulin, vascular targeting